Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy
Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the clonal proliferation of antibody producing plasma cells.Despite the use of next VITALGREENS generation proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and immunotherapy, the development of therapy refractory disease is common, with approximately 20% of MM patients suc